Pelecopan

Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases[1][2][3].

Product Specifications

CAS Number

[2378380-49-3]

Product Name Alternative

BCX9930

UNSPSC

12352005

Target

Complement System

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pelecopan.html

Concentration

10mM

Purity

98.07

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CC1=C(OCC2=CC3=C(C(C4=C(F)C(CN)=NC=C4)=C2)OC=C3)C=CC=C1)O

Molecular Formula

C23H19FN2O4

Molecular Weight

406.41

References & Citations

[1]International Nonproprietary Names for Pharmaceutical Substances (INN) |[2]AustinKulasekararajMD MRCP, FRCPath, et al. BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) . Blood (2020) Volume 136, Supplement 1, 5 November 2020, Pages 14-15|[3]XilinChenMDPhD, et al. Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH) . Blood (2020) Volume 136, Supplement 1, 5 November 2020, Page 32.